Over the past few years, the exploration of the genomic and molecular landscape of acute myeloid leukaemia (AML), identification of mutations associated with the pathogenesis and understanding of the mechanisms of resistance to treatment has led to a significant shift in the treatment paradigms for patients with AML, resulting in improved clinical outcomes.1 Nevertheless, there is a persistent high need to improve survival and quality of life for patients with AML, especially with our aging population. During the Belgian Hematology Society post- ASH 2021 meeting Dr. Spilleboudt, Jules Bordet Institute, Brussels, gave a comprehensive summary of the highlights in advancements of AML treatment ranging from first line options, treatment in relapsed/refractory (R/R) patients, maintenance, and data on the burden of care in elderly patients.

(BELG J HEMATOL 2022;13(1):48-54)